

STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Service Prior Authorization Criteria

JUXTAPID® (Iomitapide)

Effective 1/01/2018

Prior Authorization Request Form

JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)

CRITERIA FOR APPROVAL

- 1) Diagnosis of Homozygous familial hypercholesteremia (HoFH); AND
- 2) Prescriber must be enrolled in the Juxtapid REMS program; AND
- 3) Patient has had a minimum 8-week trial of Repatha, used in combination with other lipid-lowering therapies; **AND**
- Patient is currently receiving other lipid-lowering therapies (low-fat diet, apheresis, and lipid lowering agents including HMG-CoA inhibitors at the maximum tolerable dose);
 AND
- 5) Measurement of ALT, AST, alkaline phosphatase and bilirubin before initiation of therapy and before each dose increase or every month, whichever comes first during the first twelve (12) months of therapy. After the first year, all levels must be measured every three (3) months or before each dose increase, whichever comes first; **AND**
- 6) Negative pregnancy test prior to starting therapy, if at risk; AND
- 7) Capable of complying with effective contraceptive measures if at risk; AND
- 8) No concomitant use of strong CYP3E4 inhibitors (such as boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, medefradil, nedazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin or voriconazole)
- Patient must take daily supplements of vitamins containing 400 international units vitamin E and at least 200 mg linoleic acid, 210 mg ALA, 110 mg EPA, and 80 mg DHA while receiving Juxtapid.

REFERENCES

- 1) Lexicomp monograph on Juxtapid reviewed 11/9/2017
- 2) Package Insert for Juxtapid (rev 8/2017)
- 3) UpToDate Monograph: Familial hypercholesterolemia in adults: Treatment